BridgeBio Pharma - BBIO Net earnings per one share for the last twelve months

BridgeBio Pharma (BBIO) - corporate logo

BridgeBio Pharma, Inc. (BBIO) achieves high scalability by developing high-cost proprietary drugs for rare pathologies. On GURU.Markets, the annual EPS (TTM) growth trend reflects market expectations, with the indicator settling at 27.10. Business resilience is based on the flexible distribution of genetic drugs and minimal geopolitical risks due to the protected nature of the US and European markets.

BBIO: bridgebio.com Net earnings per share for the last 12 months 02/11/2024 - 11/16/2026

BridgeBio Pharma, Inc. - analytical breakdowns and key metrics (BBIO)

- stock quotes and analyst forecast:
Fundamental company valuation:BBIO - BridgeBio Pharma
Brand item of BridgeBio Corp

The analyst utilizes this indicator to verify the issuer's creditworthiness and financial stability. The development of targeted drugs for rare pathologies creates a stable foundation for the long-term growth of BridgeBio Pharma (BBIO). The annual volatility of TTM net income per share filters out market noise, measuring the actual dynamics of the business's accounting efficiency over the year. The positive trend confirms profit scaling, although it requires correlation with current market conditions.

Competitor analysis

Earnings per one share for the last 12 months VRTX|ALNY: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Insmed Inc (INSM)|UTHR (United Therapeutics Corporation) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BMRN (BioMarin)|Earnings per share for the last twelve months bgm.ltd (BGM)|COGT (Cogent Biosciences Inc) - Earnings per share for the trailing year|Earnings per share for the last twelve months Xeris Biopharma Holdings XERS|KROS (Keros Pharma) - Earnings per one share for the last 12 months|Arcturus Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ETON (Eton Pharmaceuticals)|KMDA: Net earnings per share (EPS TTM)|Fulcrum Therapeutics Inc (FULC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Rein Therapeutics Inc. RNTX|gelteq.com - Net earnings per share (EPS TTM)|AYTU - Net earnings per share (EPS TTM)|CMMB: Net earnings per share (EPS TTM)|SRx Health Solutions Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Polyrizon Ltd|AEZS (Aeterna Zentaris) - Earnings per share for the last four quarters|Earnings per share for the last twelve months CTD Holdings (CYTH)|INZY: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Reneo Pharmaceuticals Inc. RPHM|Net earnings per share for the last four quarters COSCIENS Biopharma Inc. (CSCI)